Yokohama to Host WCN’26: The World Congress of Nephrology Returns to Japan After 36 Years
26.3.2025 15:59:00 CET | Business Wire | Press release
The World Congress of Nephrology 2026 (WCN’26), the flagship event of the International Society of Nephrology (ISN), is set to take place in Yokohama from March 28 to 31, 2026. The Congress is co-hosted by the Japanese Society of Nephrology (JSN) and the Asian Pacific Society of Nephrology (APSN).
The Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama, in collaboration with the City of Yokohama, supported the bid led by Professor Masaomi Nangaku, President of the Japanese Society of Nephrology. Thanks to PACIFICO Yokohama’s excellent track record in hosting international conferences and the venue’s excellent accessibility, the bid was successfully secured.
Marking a highly anticipated return to Japan after 36 years, the prestigious WCN will bring together leading experts, researchers, and healthcare professionals dedicated to advancing kidney health worldwide. Through dynamic scientific discussions, high-level collaborations, and knowledge exchange, WCN’26 will accelerate advancements in kidney care and strengthen international partnerships.
Comment from Conference Chair, Professor Masaomi Nangaku
“We are thrilled that Yokohama has been chosen as the venue for the World Congress of Nephrology 2026. With its excellent accessibility and convenient hotels, shopping, and conference facilities, Yokohama is the perfect location to promote global collaboration in nephrology research and clinical practices, while further elevating the international presence of the Japanese Society of Nephrology.”
Event Overview
- Event Name: World Congress of Nephrology 2026 (WCN’26)
- Dates: March 28–31, 2026
- Venue: PACIFICO Yokohama
- Expected Attendance: 5,000 participants (including 2,000 from overseas)
- Organizer: International Society of Nephrology (ISN) https://www.theisn.org/
-
Previous and Future Conferences:
2025: New Delhi, India
2024: Buenos Aires, Argentina
2023: Bangkok, Thailand + Virtual
2022: Kuala Lumpur, Malaysia + Virtual
Through their support of international conferences like WCN’26, YCVB and PACIFICO Yokohama are working to boost economic development and foster new business opportunities in the region.
About the Yokohama City Visitors Bureau:
The role of the Yokohama City Visitors Bureau (YCVB) is to employ the wealth of resources existing in the City of Yokohama and Kanagawa Prefecture to promote the region as an ideal destination for both tourists and international conventions. In this way, the YCVB is contributing to the reinvigoration of the City of Yokohama and surrounding areas, and the advancement of its globalization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326550042/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom